ANTX
AN2 Therapeutics Inc
NASDAQ: ANTX · HEALTHCARE · BIOTECHNOLOGY
$4.68
-1.27% today
Updated 2026-04-29
Market cap
$156.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.16
Dividend yield
—
52W range
$1 – $7
Volume
1.7M
AN2 Therapeutics Inc (ANTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $77000.00 | — | — | — |
| Gross profit | — | — | — | $-77000.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $29.33M | $6.02M | $16.91M | $29.51M | $54.87M | $40.49M | $24.77M |
| SG&A | $1.73M | $1.26M | $4.67M | $12.75M | $14.76M | $14.07M | $13.34M |
| Operating income | $-31.07M | $-7.28M | $-21.57M | $-42.26M | $-69.64M | $-54.55M | $-38.11M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-5.18M | $-7.28M | $-21.47M | $-43.47M | $4.90M | $3.23M | $-38.11M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-36.25M | $-7.28M | $-21.57M | $-42.26M | $-64.73M | $-51.32M | — |
| Interest expense | $0.00 | $3000.00 | $69000.00 | $514000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-33.81M | $-13.60M | $-21.47M | $-41.47M | $-64.73M | $-51.32M | $-35.17M |
| Net income growth (YoY) | — | +59.8% | -57.9% | -93.1% | -56.1% | +20.7% | +31.5% |
| Profit margin | — | — | — | — | — | — | — |